Select language:  
1800 620 420
Close menu

Improving treatment of blood cancers using targeted therapies

Dr Eric Wenlong Li
Dr Eric Wenlong Li


Venetoclax, an oral anticancer drug, is highly effective against numerous blood cancers including Acute Myeloid Leukaemia (AML) and Chronic Lymphocytic Leukaemia (CLL) and is now a standard treatment for these blood cancers.

Although Venetoclax has resulted in patients experiencing longer periods of remission, for others, they inevitability relapse with little hope of a cure.


Current evidence points to sophisticated genetic and epigenetic (cell environment where genes operate) mechanisms cancer cells use to become resistant to Venetoclax.

Eric’s research will discover these mechanisms using new and advanced techniques to find the common factors that drive Venetoclax resistance, and to understand which patients will relapse on Venetoclax and will contribute to identifying ways to overcome drug resistance.


Eric’s research will change the management of blood cancer on several fronts. Firstly, his research will help other scientists to use the evidence as a roadmap for future discoveries. Secondly, his research will help provide new prognostic tools that can be used throughout the patient’s journey. Importantly, Eric’s research will help to determine optimal treatment dosage for each patient.


Eric is a haematologist who completed his haematology specialist training in NSW at Nepean, Concord, and Royal Prince Alfred Hospitals.

Eric has personally been touched by blood cancer, which propelled him to pursue a career in haematology.

Eric aspires to build a career as a molecular haematologist, leading a cutting-edge molecular laboratory that can deliver world-class personalised care for patients and support advanced molecular research.

Discover more PhD projects

Read the latest blood cancer research news

Last updated on November 13th, 2023

Developed by the Leukaemia Foundation in consultation with people living with a blood cancer, Leukaemia Foundation support staff, haematology nursing staff and/or Australian clinical haematologists. This content is provided for information purposes only and we urge you to always seek advice from a registered health care professional for diagnosis, treatment and answers to your medical questions, including the suitability of a particular therapy, service, product or treatment in your circumstances. The Leukaemia Foundation shall not bear any liability for any person relying on the materials contained on this website.